OBJECTIVE: To investigate the cost-effectiveness of a hypothetical cardioprotective agent used to reduce infarct size in patients undergoing percutaneous coronary intervention (PCI) after anterior ST-elevation myocardial infarction. METHODS: DESIGN: A cost-utility analysis using a Markov model. SETTING: The National Health Service in the UK. PATIENTS: Patients undergoing PCI after anterior ST-elevation myocardial infarction. INTERVENTIONS: A cardioprotective agent given at the time of reperfusion compared to no cardioprotection. We assumed the cardioprotective agent (given at the time of reperfusion) would reduce the risk and severity of heart failure (HF) after PCI and the risk of mortality after PCI (with a relative risk ranging from 0.6 ...
A discrete event simulation model of the patient pathways in the treatment of coronary heart disease...
Cardioprotection; Drug development; InfarctionCardioprotección; Desarrollo de fármacos; InfartoCardi...
To determine if physician subspecialization influences practice style and resource utilization, we p...
Objectives: In the follow-up of patients in a trial of intracoronary sodium nitrite given during pri...
A model was designed to examine the relations between incremental costs and benefits of coronary thr...
OBJECTIVES:: In the follow-up of patients in a trial of intracoronary sodium nitrite given during pr...
This article is based on the work from COST Action EU-CARDIOPROTECTION CA16225 supported by COST (Eu...
INTRODUCTION: Emergency percutaneous coronary intervention (PCI) of the culprit lesion for patients ...
To determine the cost-effectiveness of pravastatin therapy in patients with coronary heart disease, ...
Acute myocardial infarction (AMI) and the heart failure (HF) that often follows are the leading caus...
Aims: To estimate the costs, benefits and cost effectiveness, from the UK NHS perspective, of fluvas...
Treatment of acute myocardial infarct patients (AMI) includes rapid restoration of coronary blood fl...
CULPRIT-SHOCK is a Collaboration Project funded by the European Union under the 7th Framework Progra...
OBJECTIVE: To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa ...
Quantitative decision analyses provide a means whereby the effectiveness, in terms of patient outcom...
A discrete event simulation model of the patient pathways in the treatment of coronary heart disease...
Cardioprotection; Drug development; InfarctionCardioprotección; Desarrollo de fármacos; InfartoCardi...
To determine if physician subspecialization influences practice style and resource utilization, we p...
Objectives: In the follow-up of patients in a trial of intracoronary sodium nitrite given during pri...
A model was designed to examine the relations between incremental costs and benefits of coronary thr...
OBJECTIVES:: In the follow-up of patients in a trial of intracoronary sodium nitrite given during pr...
This article is based on the work from COST Action EU-CARDIOPROTECTION CA16225 supported by COST (Eu...
INTRODUCTION: Emergency percutaneous coronary intervention (PCI) of the culprit lesion for patients ...
To determine the cost-effectiveness of pravastatin therapy in patients with coronary heart disease, ...
Acute myocardial infarction (AMI) and the heart failure (HF) that often follows are the leading caus...
Aims: To estimate the costs, benefits and cost effectiveness, from the UK NHS perspective, of fluvas...
Treatment of acute myocardial infarct patients (AMI) includes rapid restoration of coronary blood fl...
CULPRIT-SHOCK is a Collaboration Project funded by the European Union under the 7th Framework Progra...
OBJECTIVE: To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa ...
Quantitative decision analyses provide a means whereby the effectiveness, in terms of patient outcom...
A discrete event simulation model of the patient pathways in the treatment of coronary heart disease...
Cardioprotection; Drug development; InfarctionCardioprotección; Desarrollo de fármacos; InfartoCardi...
To determine if physician subspecialization influences practice style and resource utilization, we p...